Methods of treating or preventing pain using sibutramine metabolites
US6974838B2 · kind B2 · utility
0Cited by
41References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 23, 2004 |
| Grant date | Dec 13, 2005 |
| Priority date | — |
| Expiry date | Apr 1, 2024 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of making and using racemic and optically pure metabolites of sibutramine, and pharmaceutically acceptable salts, solvates, and clathrates thereof, are disclosed. Pharmaceutical compositions and dosage forms are also disclosed which comprise a dopamine reuptake inhibitor, such as a racemic or optically pure sibutramine metabolite, and optionally an additional pharmacologically active compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.